Aprea Therapeutics, Inc. APRE
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 52.81% | 59.71% | |||
| Gross Profit | -52.81% | -60.24% | |||
| SG&A Expenses | -13.69% | 11.09% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.54% | 29.63% | |||
| Operating Income | -17.54% | -29.79% | |||
| Income Before Tax | -9.23% | -33.89% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.23% | -33.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.23% | -33.89% | |||
| EBIT | -17.54% | -29.79% | |||
| EBITDA | -17.56% | -29.85% | |||
| EPS Basic | 70.03% | 29.90% | |||
| Normalized Basic EPS | 69.98% | 29.91% | |||
| EPS Diluted | 70.03% | 29.90% | |||
| Normalized Diluted EPS | 69.98% | 29.91% | |||
| Average Basic Shares Outstanding | 264.20% | 91.02% | |||
| Average Diluted Shares Outstanding | 264.20% | 91.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||